FY2025 EPS Estimates for CalciMedica Cut by HC Wainwright

CalciMedica Inc. (NASDAQ:CALC) – Analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for CalciMedica in a research report issued on Thursday, January 29th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($1.95) per share for the year, down from their previous estimate of ($1.66). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for CalciMedica’s Q4 2025 earnings at ($0.66) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($1.06) EPS and FY2028 earnings at ($1.20) EPS.

A number of other equities research analysts have also commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of CalciMedica in a report on Wednesday, January 21st. Wall Street Zen raised shares of CalciMedica to a “sell” rating in a research note on Saturday, January 17th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $16.00.

CalciMedica Stock Performance

NASDAQ:CALC opened at $0.61 on Monday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 4.04 and a current ratio of 4.03. CalciMedica has a fifty-two week low of $0.59 and a fifty-two week high of $7.20. The firm has a market cap of $8.78 million, a PE ratio of -0.38 and a beta of 0.49. The business has a 50 day moving average price of $4.88 and a 200-day moving average price of $3.75.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.02.

Institutional Investors Weigh In On CalciMedica

Several institutional investors and hedge funds have recently modified their holdings of the stock. Sound View Wealth Advisors Group LLC purchased a new position in shares of CalciMedica during the second quarter valued at about $32,000. Cetera Investment Advisers boosted its position in CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after acquiring an additional 9,045 shares in the last quarter. Atria Investments Inc grew its holdings in shares of CalciMedica by 20.0% during the 2nd quarter. Atria Investments Inc now owns 44,700 shares of the company’s stock worth $72,000 after acquiring an additional 7,436 shares during the period. 180 Wealth Advisors LLC grew its holdings in shares of CalciMedica by 207.6% during the 2nd quarter. 180 Wealth Advisors LLC now owns 50,450 shares of the company’s stock worth $81,000 after acquiring an additional 34,050 shares during the period. Finally, Envestnet Asset Management Inc. lifted its stake in shares of CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares during the period.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.